CSL Ltd
ASX:CSL
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
256.28
312.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
CSL Ltd
CSL Ltd
Net Issuance of Common Stock
CSL Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CSL Ltd
ASX:CSL
|
Net Issuance of Common Stock
$40m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Net Issuance of Common Stock
AU$80.1m
|
CAGR 3-Years
14%
|
CAGR 5-Years
56%
|
CAGR 10-Years
28%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Net Issuance of Common Stock
$65.4m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Net Issuance of Common Stock
-AU$754.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Net Issuance of Common Stock
AU$6.7m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Net Issuance of Common Stock
AU$92.1m
|
CAGR 3-Years
31%
|
CAGR 5-Years
59%
|
CAGR 10-Years
31%
|
|
CSL Ltd
Glance View
CSL Ltd. is a global biotechnology powerhouse, rooted in Australia, that specializes in developing and delivering innovative therapies for people with serious and rare medical conditions. Founded in 1916, CSL originally focused on producing blood serum for treating was patients during World War I. Over the years, the company has evolved remarkably, moving into the biopharmaceutical realm with a strong focus on immunology, hematology, and respiratory diseases. Today, CSL is best known for its leading product, antibody therapies derived from human plasma, providing vital treatments for conditions such as hemophilia, primary immunodeficiency, and Guillain-Barré Syndrome. Investors appreciate CSL’s impressive track record of steady revenue growth, driven by increasing global demand for its life-saving products and a robust pipeline of new therapies under development. What sets CSL apart in the competitive landscape is its commitment to research and development, dedicating a significant portion of its resources to innovation that improves patient outcomes. The company's diverse global presence in over 30 countries allows it to effectively tap into various markets, making it a resilient choice for investors. With an experienced leadership team at the helm and a strong focus on sustainability and ethical practice, CSL has garnered a reputation for quality and consistency. As healthcare becomes an increasingly essential part of economies worldwide, CSL stands out with its strategic investments and partnerships aimed at expanding its market reach. For investors, CSL Ltd. represents not just a stable growth opportunity, but a chance to be part of a mission-driven organization making a significant impact on global health.
See Also
What is CSL Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
40m
USD
Based on the financial report for Jun 30, 2024, CSL Ltd's Net Issuance of Common Stock amounts to 40m USD.
What is CSL Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
5%
Over the last year, the Net Issuance of Common Stock growth was 18%. The average annual Net Issuance of Common Stock growth rates for CSL Ltd have been -11% over the past three years , 5% over the past five years .
You don't have any saved screeners yet
